TARRYTOWN, N.Y., March 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that results of the Phase 1 clinical program with their investigational product REGN727/ SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) were published in the March 22, 2012 issue of the New England Journal of Medicine. The primary author of the article, entitled "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol," was Evan A. Stein, M.D., Ph.D., Director of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio, and Principal Investigator of one of the REGN727/ SAR236553 Phase 1 clinical trials.